首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1590313

CDMO - 全球市場機會與競爭格局

Global Market Opportunities and Competitive Landscape for CDMO

出版日期: 2024年11月14日 | 出版商:

BCC Research | 英文 130 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球 CDMO 市場規模預計將從 2023 年的 1,280 億美元和 2024 年的 1,366 億美元成長到 2029年終的1,916 億美元，預測期內複合年成長率為 7.0%。

藥品/最終產品製造服務業預計將從2024年的506億美元成長到2029年終的697億美元，複合年成長率為6.6%。分析測試和監管支援服務業預計將從 2024 年的 197 億美元成長到 2029年終的299 億美元，複合年成長率為 8.7%。

該報告調查了全球 CDMO 市場，並提供了市場概況、市場影響因素和市場機會、法律制度、新興技術和技術發展趨勢、市場規模趨勢和預測以及各個細分市場和地區的細分分析。詳細分析、競爭格局、主要企業簡介等

細分細分
市場區隔：依服務類型
原料藥製造服務
製藥和最終產品製造服務
藥物開發服務
分析測試和監管支援服務
市場區隔：依分子類型
小分子藥物
生物製藥
先進的治療
市場區隔：按最終用戶
臨床
商業的
地域分佈
市場區隔：按地區
北美洲
歐洲
亞太地區
其他領域

第7章競爭訊息

概述
市場新參與企業
主要企業全球市場佔有率

第 8 章 CDMO 市場的永續性：ESG 視角

概述
綠色化學醫學製造
整個開發週期和供應鏈的永續性
CDMO 產業的永續性
環境考慮
社會考慮
管治因素
ESG風險評估
結論

第9章附錄

調查方法
來源
簡稱
公司簡介
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CATALENT INC.
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONZA
MERCK KGAA
RECIPHARM AB
SAMSUNG BIOLOGICS
SIEGFRIED HOLDING AG
THERMO FISHER SCIENTIFIC INC.
WUXI APPTEC

簡介目錄圖表

Product Code: PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

The global CDMO market for drug product/finished drug manufacturing services is expected to grow from $50.6 billion in 2024 to $69.7 billion by the end of 2029, at a CAGR of 6.6% from 2024 to 2029.

The global CDMO market for analytical testing and regulatory support services is expected to grow from $19.7 billion in 2024 to $29.9 billion by the end of 2029, at a CAGR of 8.7% from 2024 to 2029.

Report Scope

This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.

The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

76 data tables and 32 additional tables
An overview of the global contract development and manufacturing organization (CDMO) market
Analysis of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Estimates of the market size and revenue forecast for the CDMO market, and a corresponding market share analysis based on type of service, drug molecule type, end user, and region
Evaluation of the market potential and opportunities for pharmaceutical CDMOs, regulatory policies, standards and inspection trends
Identifying the pharma companies that are considered leaders in their field, as well as the technological means these companies are using to exploit their markets
A look at the competitive landscape of the global CDMO market, featuring companies contracting with a contract manufacturing outsourcer for both clinical and commercial stage manufacturing
A discussion of the ESG challenges and practices in the CDMO industry
An analysis of the market shares of key companies in the industry as well as their proprietary technologies and strategic alliances
Profiles of the leading players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Catalent Inc., and WuXi AppTec

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Value Chain Analysis
Small-Molecule Drugs
Biologics
Advanced Therapy Medical Products
PESTEL Analysis of the Pharmaceutical Industry
Political Factors
Economic Factors
Social Factors
Technological Factors
Environmental Factors
Legal Factors

Chapter 3 Market Dynamics

Global Market Dynamics
Market Drivers
Increase in Pharmaceutical Outsourcing Practices
Pressure on R&D Spending
Rising Demand for Advanced Therapeutics
Upsurge in the Number of Clinical Trials
Market Restraints
Strict Regulations and Compliance Requirements
Shortage of Skilled Technical Personnel
Strong Competition in Cost, Technology and Service Ranges
Market Opportunities
Inorganic Growth

Chapter 4 Emerging Trends

Overview
Increased Focus on Biologics and Cell and Gene Therapy
Integration of Digital Technologies
Collaborative Risk Management

Chapter 5 Regulatory Landscape

Overview
Good Manufacturing Practice (GMP)
Quality Assurance and Quality Control
Regulatory Submissions
Environmental & Safety Regulations
International Standards
Data Integrity & Security
Labeling & Packaging
Audits and Inspections

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Market Breakdown by Type of Service
API Manufacturing Services
Drug Product/Finished Drug Manufacturing Services
Pharmaceutical Development Services
Analytical Testing and Regulatory Support Services
Market Breakdown by Type of Molecule
Small-molecule Drugs
Biologics
Advanced Therapies
Market Breakdown by End User
Clinical
Commercial
Geographic Breakdown
Market Breakdown by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Overview
New Entrants in Market
Global Market Shares of Leading Companies

Chapter 8 Sustainability in CDMO Market: ESG Perspective

Overview
Green Chemistry and Pharmaceutical Manufacturing
Considering Sustainability through the Development Cycle and Across the Supply Chain
Sustainability in the CDMO industry
Environmental Considerations
Social Considerations
Governance Factors
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CATALENT INC.
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONZA
MERCK KGAA
RECIPHARM AB
SAMSUNG BIOLOGICS
SIEGFRIED HOLDING AG
THERMO FISHER SCIENTIFIC INC.
WUXI APPTEC

簡介目錄圖表

List of Tables

Summary Table : Global CDMO Market, by Type of Service, Through 2029
Table 1 : Global CDMO Market, by Type of Service, Through 2029
Table 2 : Global CDMO Market for API Manufacturing Services, by Region, Through 2029
Table 3 : Global CDMO Market for Drug Product/Finished Drug Manufacturing Services, by Region, Through 2029
Table 4 : Global CDMO Market for Pharmaceutical Development Services, by Region, Through 2029
Table 5 : Global CDMO Market for Analytical Testing and Regulatory Support Services, by Region, Through 2029
Table 6 : Global CDMO Market, by Type of Molecule, Through 2029
Table 7 : Global CDMO Market for Small-molecule Drugs, by Region, Through 2029
Table 8 : Global CDMO Market for Biologics, by Region, Through 2029
Table 9 : Global CDMO Market for Advanced Therapies, by Region, Through 2029
Table 10 : Global CDMO Market, by End User, Through 2029
Table 11 : Global CDMO Market for Clinical Services, by Region, Through 2029
Table 12 : Global CDMO Market for Commercial Services, by Region, Through 2029
Table 13 : Global Market for CDMO, by Region, Through 2029
Table 14 : North American CDMO Market, by Types of Service, Through 2029
Table 15 : North American CDMO Market, by Type of Molecule, Through 2029
Table 16 : North American CDMO Market, by End User, Through 2029
Table 17 : North American Market for CDMO, by Country, Through 2029
Table 18 : The U.S. CDMO Market, by Types of Service, Through 2029
Table 19 : The U.S. CDMO Market, by Type of Molecule, Through 2029
Table 20 : The U.S. CDMO Market, by End User, Through 2029
Table 21 : Canadian CDMO Market, by Types of Service, Through 2029
Table 22 : Canadian CDMO Market, by Type of Molecule, Through 2029
Table 23 : Canadian CDMO Market, by End User, Through 2029
Table 24 : Mexican CDMO Market, by Types of Service, Through 2029
Table 25 : Mexican CDMO Market, by Type of Molecule, Through 2029
Table 26 : Mexican CDMO Market, by End User, Through 2029
Table 27 : European CDMO Market, by Types of Service, Through 2029
Table 28 : European CDMO Market, by Type of Molecule, Through 2029
Table 29 : European CDMO Market, by End User, Through 2029
Table 30 : European Market for CDMO Market, by Country, Through 2029
Table 31 : German CDMO Market, by Types of Service, Through 2029
Table 32 : German CDMO Market, by Type of Molecule, Through 2029
Table 33 : German CDMO Market, by End User, Through 2029
Table 34 : The U.K. CDMO Market, by Types of Service, Through 2029
Table 35 : The U.K. CDMO Market, by Type of Molecule, Through 2029
Table 36 : The U.K. CDMO Market, by End User, Through 2029
Table 37 : French CDMO Market, by Types of Service, Through 2029
Table 38 : French CDMO Market, by Type of Molecule, Through 2029
Table 39 : French CDMO Market, by End User, Through 2029
Table 40 : Spanish CDMO Market, by Types of Service, Through 2029
Table 41 : Spanish CDMO Market, by Type of Molecule, Through 2029
Table 42 : Spanish CDMO Market, by End User, Through 2029
Table 43 : Italian CDMO Market, by Types of Service, Through 2029
Table 44 : Italian CDMO Market, by Type of Molecule, Through 2029
Table 45 : Italian CDMO Market, by End User, Through 2029
Table 46 : Rest of European Countries' CDMO Market, by Types of Service, Through 2029
Table 47 : Rest of European Countries' CDMO Market, by Type of Molecule, Through 2029
Table 48 : Rest of European Countries' CDMO Market, by End User, Through 2029
Table 49 : Asia-Pacific CDMO Market, by Types of Service, Through 2029
Table 50 : Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
Table 51 : Asia-Pacific CDMO Market, by End User, Through 2029
Table 52 : Asia-Pacific Market for CDMO, by Country, Through 2029
Table 53 : Chinese CDMO Market, by Types of Service, Through 2029
Table 54 : Chinese CDMO Market, by Type of Molecule, Through 2029
Table 55 : Chinese CDMO Market, by End User, Through 2029
Table 56 : Japanese CDMO Market, by Types of Service, Through 2029
Table 57 : Japanese CDMO Market, by Type of Molecule, Through 2029
Table 58 : Japanese CDMO Market, by End User, Through 2029
Table 59 : Indian CDMO Market, by Types of Service, Through 2029
Table 60 : Indian CDMO Market, by Type of Molecule, Through 2029
Table 61 : Indian CDMO Market, by End User, Through 2029
Table 62 : Rest of Asia-Pacific CDMO Market, by Types of Service, Through 2029
Table 63 : Rest of Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
Table 64 : Rest of Asia-Pacific CDMO Market, by End User, Through 2029
Table 65 : Rest of the World CDMO Market, by Types of Service, Through 2029
Table 66 : Rest of the World CDMO Market, by Type of Molecule, Through 2029
Table 67 : Rest of the World CDMO Market, by End User, Through 2029
Table 68 : ESG Risk Rankings for CDMO Companies, 2024*
Table 69 : Information Sources in this Report
Table 70 : Glossary of Terms Used in the Global CDMO Market
Table 71 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 72 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
Table 73 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 74 : Boehringer Ingelheim International GmbH: News/Recent Developments, 2021
Table 75 : Catalent Inc.: Company Snapshot
Table 76 : Catalent Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Catalent Inc.: Product Portfolio
Table 78 : Catalent Inc.: News/Key Developments, 2022-2024
Table 79 : Fujifilm Diosynth Biotechnologies: Company Snapshot
Table 80 : Fujifilm Diosynth Biotechnologies: Product Portfolio
Table 81 : Fujifilm Diosynth Biotechnologies: News/Key Developments, 2021-2024
Table 82 : Lonza: Company Snapshot
Table 83 : Lonza: Financial Performance, FY 2022 and 2023
Table 84 : Lonza: Product Portfolio
Table 85 : Lonza: News/Key Developments, 2022-2024
Table 86 : Merck KGaA: Company Snapshot
Table 87 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 88 : Merck KGaA: Product Portfolio
Table 89 : Merck KGaA: News/Key Developments, 2022
Table 90 : Recipharm AB: Company Snapshot
Table 91 : Recipharm AB: Product Portfolio
Table 92 : Recipharm AB: News/Key Developments, 2021-2024
Table 93 : Samsung Biologics: Company Snapshot
Table 94 : Samsung Biologics: Financial Performance, FY 2022 and 2023
Table 95 : Samsung Biologics: Product Portfolio
Table 96 : Samsung Biologics: News/Key Developments, 2021-2024
Table 97 : Siegfried Holding AG: Company Snapshot
Table 98 : Siegfried Holding AG: Financial Performance, FY 2022 and 2023
Table 99 : Siegfried Holding AG: Product Portfolio
Table 100 : Siegfried Holding AG: News/Key Developments, 2022-2024
Table 101 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 102 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 103 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 104 : WuXi AppTec: Company Snapshot
Table 105 : WuXi AppTec: Financial Performance, FY 2022 and 2023
Table 106 : WuXi AppTec: Product Portfolio
Table 107 : WuXi AppTec: News/Key Developments, 2022-2024

List of Figures

Summary Figure : Global CDMO Market, by Type of Service, 2021-2029
Figure 1 : Pharma Services Value Chain
Figure 2 : Market Dynamics of Global CDMO Market
Figure 3 : Global CDMO Market Share, by Type of Service, 2023
Figure 4 : Global CDMO Market Share for API Manufacturing Services, by Region, 2023
Figure 5 : Global CDMO Market Share for Drug Product/Finished Drug Manufacturing Services, by Region, 2023
Figure 6 : Global CDMO Market Share for Pharmaceutical Development Services, by Region, 2023
Figure 7 : Global CDMO Market Share for Analytical Testing and Regulatory Support Services, by Region, 2023
Figure 8 : Global CDMO Market Share, by Type of Molecule, 2023
Figure 9 : Small-molecule NCE and Biologics Approved by FDA, 2018-2023
Figure 10 : Global CDMO Market Share for Small-molecule Drugs, by Region, 2023
Figure 11 : Global CDMO Market Share for Biologics, by Region, 2023
Figure 12 : Global CDMO Market Share for Advanced Therapies, by Region, 2023
Figure 13 : Global CDMO Market Share, by End User, 2023
Figure 14 : Global CDMO Market Share for Clinical Services, by Region, 2023
Figure 15 : Global CDMO Market Share for Commercial Services, by Region, 2023
Figure 16 : Global CDMO Market Share, by Region, 2023
Figure 17 : North American CDMO Market Share, by Types of Service, 2023
Figure 18 : North American CDMO Market Share, by Type of Molecule, 2023
Figure 19 : North American CDMO Market Share, by End User, 2023
Figure 20 : North American CDMO Market Share, by Country, 2023
Figure 21 : European CDMO Market Share, by Types of Service, 2023
Figure 22 : European CDMO Market Share, by Type of Molecule, 2023
Figure 23 : European CDMO Market Share, by End User, 2023
Figure 24 : European CDMO Market Share, by Country, 2023
Figure 25 : Asia-Pacific CDMO Market Share, by Types of Service, 2023
Figure 26 : Asia-Pacific CDMO Market Share, by Type of Molecule, 2023
Figure 27 : Asia-Pacific CDMO Market Share, by End User, 2023
Figure 28 : Asia-Pacific CDMO Market Share, by Country, 2023
Figure 29 : Rest of the World CDMO Market Share, by Types of Service, 2023
Figure 30 : Rest of the World CDMO Market Share, by Type of Molecule, 2023
Figure 31 : Rest of the World CDMO Market Share, by End User, 2023
Figure 32 : Global Company Share Analysis of CDMO, 2023
Figure 33 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
Figure 34 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
Figure 35 : Catalent Inc.: Revenue Share, by Business Unit, FY 2023
Figure 36 : Catalent Inc.: Revenue Share, by Country/Region, FY 2023
Figure 37 : Lonza: Revenue Share, by Business Unit, FY 2023
Figure 38 : Lonza: Revenue Share, by Country/Region, FY 2023
Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 41 : Samsung Biologics: Revenue Share, by Business Unit, FY 2023
Figure 42 : Samsung Biologics: Revenue Share, by Country/Region, FY 2023
Figure 43 : Siegfried Holding AG: Revenue Share, by Business Unit, FY 2023
Figure 44 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
Figure 46 : WuXi AppTec: Revenue Share, by Business Unit, FY 2023
Figure 47 : WuXi AppTec: Revenue Share, by Country/Region, FY 2023